- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05178355
A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Doses Study of the Safety, Tolerability, and Pharmacokinetics of KVD824 Followed by Crossover Food Effect Sub-study in Healthy Volunteers
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Part A was a single-centre randomized, double blinded, placebo control to investigate the safety and tolerability of single ascending doses of KVD824 administered to healthy male volunteers.
Part B was a single centre, randomized, double blinded, placebo control to investigate the safety and tolerability of multiple ascending doses of KVD824 administered to healthy male volunteers.
Part C was a single-centre, open labelled to investigate the food effect.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Merthyr Tydfil, Royaume-Uni
- KalVista Investigative Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy male subjects between 18 and 55 years of age.
- Healthy subjects as determined by past medical history and as judged by the Chief Investigator / deputy.
- Male subject willing to wear a condom and whose partner of child bearing potential uses a highly effective method of contraception (e.g. partner use of intrauterine device (IUD)) or an effective method of contraception, i.e., established method of contraception + condom, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of IMP. Men whose partners are already pregnant must continue to use a condom during the trial and for three months thereafter.
- Subject with a body mass index (BMI) of 18-32 kg/m2.
- Subject with no clinically significant history of previous allergy / sensitivity to KVD824 or any of the excipients contained within the Investigational Medicinal Product.
- Subject with no clinically significant abnormal serum biochemistry, haematology, clotting profiles, and urine examination values within 28 days before the first dose of Investigational Medicinal Product.
- Subject with a negative urinary drugs of abuse screen, determined within 28 days before the first dose of Investigational Medicinal Product (N.B. a positive result may be repeated at the Chief Investigator's discretion).
- Subject with negative human immunodeficiency virus (HIV) and hepatitis B surface antigen (Hep B) and hepatitis C virus antibody (Hep C) results.
- Subject with no clinically significant abnormalities in 12-lead electrocardiogram (QTcF ≤ 430 ms and PR interval 120-220 ms) determined within 28 days before first dose of Investigational Medicinal Product.
- Subject with no clinically significant abnormalities in vital signs (supine systolic (≤140 mmHg) and diastolic blood pressure (≤ 90 mmHg), pulse (≤ 100 bpm), oral temperature (≤ 37.5°C)) determined within 28 days before first dose of Investigational Medicinal Product.
- Subjects must not donate sperm from first dose until at least 3 months after last dose of Investigational Medicinal Product.
- Subjects without any special food restrictions that would hinder ability to consume gelatin (Part A and Part B placebo), or the high fat breakfast provided during study Part C; such as vegetarian, lactose intolerance, vegan, low-fat, low sodium, etc.
- Subjects with no known allergy or sensitivity to lactose and/or any additional excipients contained in Investigational Medicinal Product.
- Subject must be available to complete the study (including all follow up visits).
- Subject must satisfy the Chief Investigator / deputy about their fitness to participate in the study.
- Subject must provide written informed consent to participate in the study.
Exclusion Criteria:
- A clinically significant history of gastrointestinal disorder likely to influence Investigational Medicinal Product absorption.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 28 days or 5 half-lives (which ever is longer) prior to the first dose of Investigational Medicinal Product, unless in the opinion of the Chief Investigator the medication will not interfere with the study procedures or compromise subject safety.
- Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
- Subjects with a history of clotting abnormalities.
- A clinically significant history of drug or alcohol abuse in the last 5 years.
- Users of nicotine products i.e., current smokers or ex-smokers who have smoked within the 6 months prior to dosing with the study medication or users of cigarette replacements (e.g., e-cigarettes, nicotine patches or gums).
- Inability to communicate well with Investigators (i.e., language problem, poor mental development or impaired cerebral function).
- Participation in a New Chemical Entity clinical study within the previous 3 months or a marketed drug clinical study within the 30 days before the first dose of Investigational Medicinal Product. (Washout period between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
- Donation of 450 mL or more blood within the 3 months before the first dose of Investigational Medicinal Product.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Part A - KVD824 - 10 mg
6 participants were administered10 mg of KVD824 in capsule form (1 x 10 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part A - KVD824 - 20 mg
6 participants were administered 20mg of KVD824 in capsule form ( 2 x 10 mg capsules) on one occasion on Day 1. 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part A - KVD824 - 40 mg
6 participants were administered 40mg of KVD824 in capsule form (1 x 40 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part A - KVD824 - 80 mg
6 participants were administered 80mg of KVD824 in capsule form (2 x 40 mg capsules) on one occasion on Day 1. 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part A - KVD824 - 160mg
6 participants were administered 160mg of KVD824 in capsule form (1 x 160 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part A - KVD824 - 320 mg
6 participants were administered 320mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part A - KVD824 - 640 mg
6 participants were administered 640 mg of KVD824 in capsule form (2 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part A - KVD824 - 1280 mg
6 participants were administered 1280 mg of KVD824 in capsule form (4 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part B - KVD824 - 80 mg Multi-Dose
6 participants were administered 80 mg of KVD824 in capsule form (2 x 40 mg capsules) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part B - KVD824 - 160 mg Multi-Dose
6 participants were administered 160mg of KVD824 in capsule form (1 x 160 mg capsule) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part B - KVD824 - 320 mg Multi-Dose
6 participants were administered 320mg of KVD824 in capsule form (1 x 320 mg capsule) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part B - KVD824 - 640 mg Multi-Dose
6 participants were administered 640mg of KVD824 in capsule form (2 x 320 mg capsules) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
|
Active
Placebo
|
Expérimental: Part C - KVD824 - 320 mg Fasted
12 participants were administered 320 mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1 in a fasted state.
|
Active
|
Expérimental: Part C - KVD824 - 320 mg High fat breakfast
12 participants were administered 320 mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1 following consumption of a high fat breakfast.
|
Active
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Safety - Treatment Emergent Adverse Events
Délai: Part A Days 0-10; Part B Days 0-12
|
Number of Subjects with Treatment Emergent Adverse Events
|
Part A Days 0-10; Part B Days 0-12
|
Safety - Vital signs
Délai: Part A: Days (-1)-10;Part B: Days (-1)-12
|
Number of participants with clinically significant changes in vital signs
|
Part A: Days (-1)-10;Part B: Days (-1)-12
|
Safety - Laboratory Parameters
Délai: Part A: Days (-1)-10;Part B: Days (-1)-12
|
Number of participants with clinically significant changes in laboratory assessments
|
Part A: Days (-1)-10;Part B: Days (-1)-12
|
Safety - ECG change in QTcF
Délai: Part A: Days (-1)-10; Part B: Days (-1)-12
|
Number of subjects who had any increase in QTcF parameters.
|
Part A: Days (-1)-10; Part B: Days (-1)-12
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Pharmacokinetic - Maximum Concentration (Cmax)
Délai: Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of Cmax in all cohorts of Part A, B and C.
|
Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Time to maximum concentration (Tmax)
Délai: Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of Tmax for Part A, Part B and Part C
|
Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Terminal Elimination Rate Constant (Kel)
Délai: Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of Kel in Part A, Part B and Part C
|
Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Terminal elimination half-life (t1/2)
Délai: Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of t1/2 in Part A, Part B and Part C
|
Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Area under the concentration-time curve from time 0 to 24 hour post dose (AUC0-24)
Délai: Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of AUC (0-24) in Part A, Part B and Part C
|
Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Area under the concentration-time curve from time 0 to last measurable time-point (AUC0-t)
Délai: Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of AUC (0-t) in Part A and Part C
|
Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Area under the concentration-time curve from time 0 to infinity (AUC0-inf)
Délai: Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of AUC (0-inf) in Part A, Part B and Part C
|
Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Residual Area under the curve (AUC%extrap)
Délai: Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of AUC%extrap in Part A, Part B and Part C
|
Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Apparent total body clearance (CL/F)
Délai: Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of CL/F in Part A, Part B and Part C
|
Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Apparent Volume of Distribution (Vz/F)
Délai: Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of Vz/F in Part A, Part B and Part C
|
Part A: Predose and up to 18 samples over a 48 hour period post dose; Part B: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5; Part C: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Area under the curve from time of first dose to 12 h post-dose (AUC0-12)
Délai: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5
|
Evaluation of AUC0-12 in Part B
|
Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5
|
Pharmacokinetic - Area under the curve from time of second dose to 12 h post-dose (AUC12-24)
Délai: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5
|
Evaluation of AUC12-24 in Part B
|
Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5
|
Pharmacokinetic - Apparent total body clearance at steady state (CLss/F)
Délai: Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5
|
Evaluation of Clss/F in Part B
|
Pre-dose and up to 11 samples over a 24 hour period post morning dose, day 1 and 5
|
Pharmacokinetic - Maximum Concentration (Cmax) - Bioavailability Ratio Fed/Fasted
Délai: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of Cmax Bioavailability Ratio Fed/Fasted in Part C
|
Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Area under the curve from the time of dosing to the time of the last measurable concentration (AUC 0-t) - Bioavailability Fed/Fasted Ratio
Délai: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of AUC0-t Bioavailability Ratio Fed/Fasted in Part C
|
Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Pharmacokinetic - Area under the concentration-time curve from time 0 to infinity(AUC0-inf) - Bioavailability Fed/Fasted Ratio
Délai: Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Evaluation of AUC0-inf Bioavailability Ratio Fed/Fasted in Part C
|
Predose and up to 16 samples over a 24 hour period post dose per treatment period.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Study Director, KalVista Pharmaceuticals
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies cardiovasculaires
- Maladies vasculaires
- Maladies de la peau
- Syndromes d'immunodéficience
- Maladies du système immunitaire
- Hypersensibilité immédiate
- Maladies génétiques, innées
- Maladies de la peau, vasculaire
- Hypersensibilité
- Urticaire
- Maladies héréditaires de déficience du complément
- Maladies d'immunodéficience primaire
- Angiœdème
- Angiœdème, héréditaire
Autres numéros d'identification d'étude
- KVD824-101
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur KVD824
-
KalVista Pharmaceuticals, Ltd.Complété
-
KalVista Pharmaceuticals, Ltd.RésiliéAngiœdème, héréditaire, types I et IIÉtats-Unis, Tchéquie, Allemagne, Hongrie, Italie, Macédoine du Nord, Royaume-Uni, Australie, Bulgarie, Canada, France, Nouvelle-Zélande, Porto Rico